Table 1 Basic information of the included literature
No. | First author | Publication year | Country of patient | Age | Sample size (M/F) | Outcome indicators | ||
|---|---|---|---|---|---|---|---|---|
Test | Control | Test | Control | |||||
1 | Jie Di | 2021 | China | 71.1 ± 2.6 | 70.3 ± 3.5 | 85 (46/39) | 82 (43/39) | 1,2,4,8 |
2 | Suping Huang | 2021 | China | 63.57 ± 5.25 | 63.11 ± 6.14 | 54 (35/19) | 54 (31/23) | 1,2,3,4,5,6 |
3 | Anil K Malik1 | 2021 | India | 37.72 ± 15.93 | 46.40 ± 18.05 | 25 (13/12) | 25 (10/15) | 1,2, 6 |
4 | Mengxia Chen | 2020 | China | 56.59 ± 14.73 | 62.94 ± 12.93 | 34 (16/18) | 32 (18/14) | 1,2,5,6 |
5 | Jie Chen | 2016 | China | 56.5 ± 15.4 | 55.7 ± 14.8 | 100 (52/48) | 100 (54/46) | 1,2,4 |
6 | Jinling Gu | 2018 | China | 49.9 ± 7.17 | 51.17 ± 6.69 | 35 (19/16) | 35 (18/17) | 1,2,3,4,5,7 |
7 | Liping Yuan | 2018 | China | 15–90 | 14–91 | 229 (152/77) | 162 (98/64) | 1 |
8 | Shanyi Jin | 2019 | China | 65.87 ± 16.13 | 64.94 ± 16.29 | 233 (158/75) | 220 (142/78) | 1,2 |
9 | Xiaoxiang Jiang | 2019 | China | 72.50 ± 6.40 | 72.40 ± 6.8 | 50 (29/21) | 50 (28/22) | 8 |
10 | Yaqiong Jiang | 2021 | China | 74.5 ± 14.5 | 75.3 ± 15.8 | 60 | 60 | 1,2,3,4,5,7 |
11 | Yingqin Li | 2021 | China | 46. 41 ± 2. 89 | 45. 82 ± 2. 71 | 48 (30/18) | 48 (25/23) | 1,2,3,5 |
12 | Yuexia Li | 2021 | China | 45.8 ± 13.8 | 44.8 ± 14.2 | 33 (15/18) | 33 (16/17) | 1,4 |
13 | Huaying Lin | 2021 | China | 59.41 ± 4.14 | 58.19 ± 3.75 | 30 (16/14) | 30 (18/12) | 4 |
14 | Qiang Song | 2021 | China | 54.06 ± 1.23 | 53.13 ± 1.42 | 30 (14/16) | 30 (13/17) | 1,3 |
15 | Sha Yu | 2023 | China | 64.93 ± 15.05 | 60.38 ± 15. 12 | 45(24/21) | 45(26/19) | 1,2,3,5 |
16 | Junyi Han | 2023 | China | 45. 31 ± 5. 26 | 45. 75 ± 5. 92 | 46(23/23) | 46(22/24) | 1,3,5,7 |
17 | Zongjia Yue | 2023 | China | 64.92 ± 6.35 | 65.37 ± 3.24 | 214(136/78) | 214(140/74) | 1,2,3,5 |
18 | Tuyong Liang | 2023 | China | 54.87 ± 14.51 | 54.92 ± 14.28 | 50(26/24) | 50(30/20) | 1,2,5 |